NCT06167642View on ClinicalTrials.gov

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Enrolling by invitationOBSERVATIONAL
Enrollment

75

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Multiple SclerosisTomography, Optical CoherenceRetinal DegenerationVisual Acuity
Interventions
DRUG

Ofatumumab

Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study

Trial Locations (1)

21287

Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Johns Hopkins University

OTHER